FDA authorizes trial of stem cell eye treatment

02/16/2012 | Modern Medicine

The FDA has cleared StemCells' experimental neural stem cell therapy for use in a Phase I/II clinical trial for dry age-related macular degeneration. The open-label, dose-escalation trial will involve 16 patients. Results of a preclinical study showed the stem cell treatment can protect photoreceptors and save vision in an animal model of retinal disease.

View Full Article in:

Modern Medicine

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA